Causal role for JAK2 V617F in thrombosis

Angela G. Fleischman, Jeffrey Tyner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The article by Takahashi and colleagues is impactful because it helps validate the decision of both sets of response criteria that focus on peripheral blood analysis for the assessment of the JAK2 V617F allele burden. The quality demonstration in a high number of samples across MPNs demonstrating the interchangeable nature of measuring alleleburden in blood and bone marrow will be very helpful in clinical trials moving forward, as well as potentially clinical practice as we further validate the impact that reduction in allele burden is helpful. In addition, it helps validate the practice even today of monitoring the JAK2 V617F allele burden in patients post stem cell transplantation in terms of monitoring for both response and relapse. As the current clinical trials of MPNs are evolving from single agent to combination strategies, the ability to dynamically follow allele burden in the course of these trials through the peripheral blood is an important advancement.Whether in the future monitoring the lower prevalence MPN molecular mutations will be helpful in assessment of therapeutic response remains a question to be answered.

Original languageEnglish (US)
Pages (from-to)3705-3706
Number of pages2
JournalBlood
Volume122
Issue number23
DOIs
StatePublished - Nov 28 2013

Fingerprint

Thrombosis
Blood
Alleles
Monitoring
Clinical Trials
Stem cells
Bone
Stem Cell Transplantation
Demonstrations
Bone Marrow
Recurrence
Mutation
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Causal role for JAK2 V617F in thrombosis. / Fleischman, Angela G.; Tyner, Jeffrey.

In: Blood, Vol. 122, No. 23, 28.11.2013, p. 3705-3706.

Research output: Contribution to journalArticle

Fleischman, Angela G. ; Tyner, Jeffrey. / Causal role for JAK2 V617F in thrombosis. In: Blood. 2013 ; Vol. 122, No. 23. pp. 3705-3706.
@article{882132872c4845aeaa8ca4d19eb2f292,
title = "Causal role for JAK2 V617F in thrombosis",
abstract = "The article by Takahashi and colleagues is impactful because it helps validate the decision of both sets of response criteria that focus on peripheral blood analysis for the assessment of the JAK2 V617F allele burden. The quality demonstration in a high number of samples across MPNs demonstrating the interchangeable nature of measuring alleleburden in blood and bone marrow will be very helpful in clinical trials moving forward, as well as potentially clinical practice as we further validate the impact that reduction in allele burden is helpful. In addition, it helps validate the practice even today of monitoring the JAK2 V617F allele burden in patients post stem cell transplantation in terms of monitoring for both response and relapse. As the current clinical trials of MPNs are evolving from single agent to combination strategies, the ability to dynamically follow allele burden in the course of these trials through the peripheral blood is an important advancement.Whether in the future monitoring the lower prevalence MPN molecular mutations will be helpful in assessment of therapeutic response remains a question to be answered.",
author = "Fleischman, {Angela G.} and Jeffrey Tyner",
year = "2013",
month = "11",
day = "28",
doi = "10.1182/blood-2013-10-531665",
language = "English (US)",
volume = "122",
pages = "3705--3706",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Causal role for JAK2 V617F in thrombosis

AU - Fleischman, Angela G.

AU - Tyner, Jeffrey

PY - 2013/11/28

Y1 - 2013/11/28

N2 - The article by Takahashi and colleagues is impactful because it helps validate the decision of both sets of response criteria that focus on peripheral blood analysis for the assessment of the JAK2 V617F allele burden. The quality demonstration in a high number of samples across MPNs demonstrating the interchangeable nature of measuring alleleburden in blood and bone marrow will be very helpful in clinical trials moving forward, as well as potentially clinical practice as we further validate the impact that reduction in allele burden is helpful. In addition, it helps validate the practice even today of monitoring the JAK2 V617F allele burden in patients post stem cell transplantation in terms of monitoring for both response and relapse. As the current clinical trials of MPNs are evolving from single agent to combination strategies, the ability to dynamically follow allele burden in the course of these trials through the peripheral blood is an important advancement.Whether in the future monitoring the lower prevalence MPN molecular mutations will be helpful in assessment of therapeutic response remains a question to be answered.

AB - The article by Takahashi and colleagues is impactful because it helps validate the decision of both sets of response criteria that focus on peripheral blood analysis for the assessment of the JAK2 V617F allele burden. The quality demonstration in a high number of samples across MPNs demonstrating the interchangeable nature of measuring alleleburden in blood and bone marrow will be very helpful in clinical trials moving forward, as well as potentially clinical practice as we further validate the impact that reduction in allele burden is helpful. In addition, it helps validate the practice even today of monitoring the JAK2 V617F allele burden in patients post stem cell transplantation in terms of monitoring for both response and relapse. As the current clinical trials of MPNs are evolving from single agent to combination strategies, the ability to dynamically follow allele burden in the course of these trials through the peripheral blood is an important advancement.Whether in the future monitoring the lower prevalence MPN molecular mutations will be helpful in assessment of therapeutic response remains a question to be answered.

UR - http://www.scopus.com/inward/record.url?scp=84891108814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891108814&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-10-531665

DO - 10.1182/blood-2013-10-531665

M3 - Article

C2 - 24288407

AN - SCOPUS:84891108814

VL - 122

SP - 3705

EP - 3706

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -